PT1001B, in conjunction with an anti-PD-L1 antibody, enhances the inhibition of PD-L1 expression in tumor cells and the infiltration of CD8+ lymphocytes, and reduces PD-1+ leukocytes in vivo, thereby augmenting the efficacy of the immune checkpoint inhibitor in a PDAC model system. The gene discussed is CD274; the disease is neoplasm.